PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 1 of 15   
STUDY TITLE:  
 
A Randomized  Controlled  Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397352]:  
 
Department of Anesthesiology and Perioperative Medicine , Tufts Medical Center  
 
PRINCIPAL INVESTIGATOR  
 
[INVESTIGATOR_154470], MD  
Assistant [CONTACT_397401] of Medicine  
Department of Anesthesiology and Perioperative Medicine  
Tufts Medical Center  
Phone: [PHONE_3457]  
Email: [EMAIL_3172]  
 
 
CO-INVESTIGATOR  
 
Alaa Basura , MD  
Post Doctoral Research Fellow  
Tufts University School of Medicine  
Department of Anesthesiology and Perioperative Medicine  
Tufts Medical Center  
Phone: [PHONE_8260]  
Email: abasura @tuftsmedicalcenter.org  
 
 
 
 
 
 
 
 
 
 
Tufts Health Sciences IRB 
Protocol Template  
Template Revised: 08/16/2016  
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 2 of 15   
Table of Contents  – Click on the links below to go directly to the applicable section  
 
1. Study Schema  ................................ ................................ ................................ ................................ ................................ .......................  3 
2. Introduction  ................................ ................................ ................................ ................................ ................................ ..........................  3 
2.1 Background and Rationale  ................................ ................................ ................................ ................................ ..............................  3 
2.2 Risks to Subjects  ................................ ................................ ................................ ................................ ................................ .............  3 
2.3 Potential Benefits to Subjects  ................................ ................................ ................................ ................................ ..........................  4 
2.4 Alternatives  ................................ ................................ ................................ ................................ ................................ .....................  4 
3 Objectives  ................................ ................................ ................................ ................................ ................................ .............................  4 
4 Enrollment and Withdrawal  ................................ ................................ ................................ ................................ ................................ . 5 
4.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ................................ .............  5 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ................................ ............  5 
4.3 Withdrawal of Subjects  ................................ ................................ ................................ ................................ ................................ ... 5 
4.4 Recruitment and Retention  ................................ ................................ ................................ ................................ ..............................  5 
4.4.1  Local Recruitment Methods  ................................ ................................ ................................ ................................ ..................  5 
4.4.2  Study -Wide Recruitment Methods  ................................ ................................ ................................ ................................ ........  5 
4.4.3  Payment  ................................ ................................ ................................ ................................ ................................ .................  5 
4.4.4  Reimbursement  ................................ ................................ ................................ ................................ ................................ ...... 6 
5 Study Design  ................................ ................................ ................................ ................................ ................................ ........................  6 
5.1 Study Timelines  ................................ ................................ ................................ ................................ ................................ ...............  6 
5.2 Procedures  ................................ ................................ ................................ ................................ ................................ .......................  6 
5.3 Evaluations  ................................ ................................ ................................ ................................ ................................ ......................  7 
5.4 Collection and Storage of Human Biological Specimens (Tissue Banking) ................................ ................................ ...................  [ADDRESS_500045] the Privacy Interests of Subjects  ................................ ................................ ................................ ...................  8 
6.5 Provisions to Monitor the Study to Ensure the Safety of Subjects  ................................ ................................ ................................ . 8 
6.6 Compensation for Research -Related Injury  ................................ ................................ ................................ ................................ .... 8 
6.7 Economic Burden to Subjects  ................................ ................................ ................................ ................................ .........................  8 
6.10 Vulnerable Populations  ................................ ................................ ................................ ................................ ................................ .........  8 
7 Adverse Event Monitoring  ................................ ................................ ................................ ................................ ................................ ... 9 
7.1 Definitions  ................................ ................................ ................................ ................................ ................................ .....................  10 
7.2 Reporting Procedures  ................................ ................................ ................................ ................................ ................................ .... 10 
7.3 Reportable New Information  ................................ ................................ ................................ ................................ .........................  10 
8 Statistical Considerations  ................................ ................................ ................................ ................................ ................................ ... 10 
8.1 Study Endpoints  ................................ ................................ ................................ ................................ ................................ ............  10 
8.2 Statistical Analysis  ................................ ................................ ................................ ................................ ................................ ........  10 
8.3 Number of Subjects  ................................ ................................ ................................ ................................ ................................ ....... 10 
8.4 Data Management ................................ ................................ ................................ ................................ ................................ ..........  11 
8.5 Randomization ................................ ................................ ................................ ................................ ................................ ...............  11 
9 Drugs or Devices  ................................ ................................ ................................ ................................ ................................ ................  11 
10 Study Administration  ................................ ................................ ................................ ................................ ................................ .........  13 
10.1 Setting  ................................ ................................ ................................ ................................ ................................ ............................  13 
10.2 Registration  ................................ ................................ ................................ ................................ ................................ ...................  13 
10.3 Resources Available  ................................ ................................ ................................ ................................ ................................ ...... 14 
10.4 IRB Review  ................................ ................................ ................................ ................................ ................................ ...................  14 
10.5 Multi -Site Research  ................................ ................................ ................................ ................................ ................................ ....... 14 
10.6 Community -Based Participatory Research  ................................ ................................ ................................ ................................ ... 14 
10.7 Sharing Results with Subjects  ................................ ................................ ................................ ................................ .......................  14 
11 References  ................................ ................................ ................................ ................................ ................................ ..........................  14 
 
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 3 of 15  1. Study Schema  
 
Enrollment  Randomization  Arm 1 8 patients  Bupi[INVESTIGATOR_397353] 2 8 patients  Chloroprocaine  
 
2. Introduction  
2.1 Background and Rationale  
 
Cervical cerclage is an ambulatory surgical procedur e of short duration commonly performed under 
neuraxial anesthesia . While  bupi[INVESTIGATOR_397354], its duration of 
action is significantly longer than that of the typi[INVESTIGATOR_397355].  (1) Chloroproca ine is another local 
anesthetic of shorter duration that has been used for neuraxial anesthesia in a variety of outpatient proc edures, 
including procedures on the perineum. One of the major advantages of chloroprocaine is  faster block resolution 
and earlier hospi[INVESTIGATOR_2345] c ompared with spi[INVESTIGATOR_58067] . (2,3) Chloroprocaine  is also considered safer 
that other local anesthetics because the risk of transient neurologic symptoms is exceedingly low . (4) Bupi[INVESTIGATOR_397356] (e.g. bulging bag ), 
but oftentimes the choice between chloroprocaine and bupi[INVESTIGATOR_397357]; good scientific 
practice would mean that we better understand the differ ences, and use the medications when clinically indicated . 
Both local anesthetics are currently used at Tufts Medical Center for spi[INVESTIGATOR_397358], but how their use impacts clinical care, in particular patient flow , is no t well understood . A 
similar randomized controlled trial at Columbia University is currently comparing bupi[INVESTIGATOR_397359] , but differs from our study in several important ways.  (5) First, we are not using 
fentany l in our study because its use results in side effects, most significantly pruritus. Second, although the dose 
of chloroprocaine and bupi[INVESTIGATOR_397360], the doses are adequate for 
the duration of procedure as per formed at Tufts Medical Center  and within the standard of care  at Tufts Medical 
Center . Finally, while Columbia is enrolling [ADDRESS_500046] of these two drugs on duration of motor block and duration until meeting 
discharge criteria. Our hypothesis is that chloroproc aine will result in faster resolution of motor block and meeting 
dischrage criteria earlier.  
 
• Is there an active control group?   
 
 
2.2 Risks to Subjects ` 
 
The risks of spi[INVESTIGATOR_397361], vomiting, hypotension, pruritis, and postdural puncture headache. 
Given that these side effects are expected and commonly occur with spi[INVESTIGATOR_397362], they will be managed according to our standard practices, including giving the patient antiemetics 
and pressers .  
 
The risks of patient randomized to bupi[INVESTIGATOR_397363], nervousness, agitation, drowsiness, 
apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respi[INVESTIGATOR_397364]. Other, more serious effects seen with IV use of this drug, particularly when it is 
administered rapi [INVESTIGATOR_375], are cardiovascular collapse, central nervous system depression, and/or hypotension.  We do 
not intend on using this medication IV.   
 
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.[ADDRESS_500047] protected, encrypted, Box storage account , which is compli ant with institutional policies 
regarding HIPAA and the IT department.  
 
2.3 Potential Benefits to Subjects  
 
Potential benefits to subjects include  faster recovery from anesthesia and quicker discharge to home  in those 
who are randomized to chloroprocaine . The benefits of subjects randomized to bupi[INVESTIGATOR_397365]. Benefits 
also include improving our scientific understanding of local anesthetics and an overall improvement to our 
society.  
 
2.4 Alternatives  
 
The alt ernative is not participating in the study.  
 
3 Objectives  
 
This objective of this study is to compare the effects of chloroprocaine vs. bupi[INVESTIGATOR_397366].  
 
• Primary  Outcome:  
➢ Duration  of motor block [Time  Frame:  6 hours]  
o The start time is defined as the moment the intrathecal local anesthetic is injected , while the 
end time is defined as the moment when the subject has no motor block ( as measured on the 
Bromage scale ). We will then subtract the two times to get the duration of motor block.  
  
• Secondary Outcome s: 
➢ Time to resolution of sensory block [Time  Frame:  6 hours]  
o The start time is defined as the moment the intrathecal local anesthetic is injected, while the 
end time is defined as the moment when the subject has no more sensory block as tested 
conventionally. We will then subtract the two times to get the duration of sensory block.  
➢ Time to ambulation [Time  Frame:  6 hours ] 
o The start time is defined as the moment the intrat hecal local anesthetic is injected, while the 
end time is defined as the moment when the subject walks for the first time postoperatively. 
We will then subtract the two times to get the time to ambulation.  
➢ Time to micturation  [Time  Frame:  6 hours ] 
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.[ADDRESS_500048] the two times to get the time to micturation . 
 
 
4 Enrol lment and Withdrawal  
4.1 Inclusion  Criteria  
• Female  
• Age: 18-45 years  old 
• BMI ≤  50 kg/m2 
• Singleton pregnancy  
• ASA classification II or III 
• Simple prophylactic cervical cerclage  
• Planning neuraxial anesthesia  
 
4.2 Exclusion Criteria  
• Abdominal cerclage  
• Complex cervical cerclage (e.g. bulging bag ) 
• Contraindication to neuraxial anesthesia  
• Known hypersensitivity to chloroprocaine (a.k.a. Ester allergy ) 
• Known hypersensitivity to paraaminobenzoic acid (PABA)  
• Known hypersensitivity to bupi[INVESTIGATOR_10319] (a.k.a. Amide allergy ) 
• Pseudocholinesterase deficiency  
• Concomitant use with ergot -type oxytocic drugs  
 
4.[ADDRESS_500049]. 
Basura,  will meet with the patients and discuss the study with them further. If they agree to participate, 
informe d consent will be obtained.  
4.4.2 Study -Wide Recruitment Methods  
Is this a multicenter study where subjects will be recruited by [CONTACT_397393] (e.g., call centers, national advertisements)?  
 
4.4.3 Payment  
Will subjects receive money, gifts, or any other incentive for participatin g in this study?  
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 6 of 15       
4.4.4 Reimbursement   
Will subjects be reimbursed for their expenses, such as travel, parking, meals, or any other study related 
costs?  
                                     
 
5 Study Design  
 
5.1 Study Timelines  
• Individuals will participate for  the duration of the anesthetic (typi[INVESTIGATOR_16195] [ADDRESS_500050] up to 6 hours in rare cases) . 
• We expect recruitment to take approximately one year.  
• The estimated date for primary analyses will be October 2018  
• For each individual there will only be one study visit lasting no more than 6  hours. It will include 
acquiring the patient consent, administering  the spi[INVESTIGATOR_72163] , and following up until the time 
of discharge to home  
•  
5.2 Procedures  
• Is there a placebo con trol arm?  
  
We will perform a prospective, randomized, double blinded clinical trial.   
 
Participa nts meeting inclusion criteria  will be approached  by [CONTACT_22888]-investigator, [CONTACT_397402],  on the day of 
surgery. The research study will be explained and they will be given an informed consent form to read. After the 
participant has had adequate  time to read through the informed consent form, think about the risks and benefits, 
and ask questions, she will be asked to  sign the form if she wishes to participate in the study. The informed 
consent form will then be stored in the principal investigator’s locked office.  
 
Once a study subject is enrolled, the co-investigator, [CONTACT_397402],  will give an opaque envelope to the study 
subject’s assigned anesthesia provider , who will be asked to open the envelope in a separate room and prepare the 
medication, either chloroprocaine  PF 40 mg (p ure Nesacaine  MPF  2% in a total volume of 2ml) , or b upi[INVESTIGATOR_10319] 
7.5 mg (pure  Sesnorcaine 0.75% diluted with normal saline to a total volume of 2ml).  The medication will be 
prepared according to standard preparation of intrathecal drug, including wipi[INVESTIGATOR_397367]. The anesthesia provider will be told that this is a blinded 
study and asked not to reveal the randomization group to the patient or any research personnel . Both drugs have 
the same  volume and color further ensuring  blindness.   
 
Upon entry into the operating room, the study subject will undergo the spi[INVESTIGATOR_397368]. No additional medications affecting motor block will be 
given, which is part of the standard  of care at Tufts Medical Center. Furthermore, the local anesthetic will be 
administered as a single dose and never repeated.   
 
Neonates will be monitored for safety by [CONTACT_397394].  
 
Immediately afterwards, the co-investigator, [CONTACT_397402],  will begin to evaluate the patient’s motor and sensory 
block in [ADDRESS_500051] as not to interfere with the 
Yes
No
Yes
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 7 of 15  surgery, and if for any reason at any time interval it is not possible to evaluate, the reason will be noted. The 
motor block will be evaluated according to the Bromage scal e, where : 
I = free movement of feet, legs and hip = No block  
II = able to flex knees, with fre e movement of feet = Mild block  
III = unable to flex knees, but with free mo vement of feet = Moderate block  
IV = unable to move leg s or feet = Complete block  
 
Upon resolution of motor block, the co-investigator, [CONTACT_397402],  will ask the part icipa nt if she can walk. Any 
ambulation will be done with a nurse to ensure the participant does not fall and hurt herself. The part icipant will 
also be asked to urina te, and the time she urinates will be recorded. Once the participant has resolution of motor 
and sensory block, can ambulate, and can micturate, the study will cease and the co-investigator, [CONTACT_397402],  will 
thank the participant for her participation in t he study. All data will be recorded on the data collection form (see 
attached form).  
 
5.3 Evaluations  
Will you perform any laboratory tests for this study?  
  
5.4 Collection and Storage of Human Biological Specimens (Tissue Banking)  
Will biological specimens be stored for future, unspecified , research?   
  
6 Ethics and  Protection of Human Subjects  
6.1 Informed Consent Process  
Will subjects be required to provide informed consent ? 
  
• The informed consent will take place  in the pre-operative patient area.   
• The patient  will have one hour before the start of the procedure to make a  decision regarding 
enrollment.  
• The consent will be obtained in  person and documented in  writing  according to  SOP: Informed 
Consent  Process for Research (HRP -090) 
• Non-English speakers will be enrolled using interpreters and IRB approved Short Forms per the 
IRB’s Short Form policy  
 
6.2 Waiver or Alteration of Consent Process  
 
• Is a waiver or alteration of the consent process be ing requested for this study ?  
  
• Is a waiver of the consent process be ing requested for parents  for research involving childre n?  
 
  
• Is a waiver of the consent process for planned emergency research  being requested ?  
  
 
6.3 Confidentiality  
 
In order to maintain confidentiality, the following mea sures will be taken:  
Yes
No
Yes
No
Y es
No
Yes
No
Yes
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 8 of 15  • All study related materials, including consent forms and d ata collection forms, will be stored in 
the principal investigator’s locked office  
• The principal investigator  [INVESTIGATOR_6254]-investigators  will have exclusive access to the form s 
• Digital data will be stored in a  hospi[INVESTIGATOR_212729], password protected,  Box account  
• Records will be stored for [ADDRESS_500052] with any member of the research team is optional, and that the 
information they share will be strictly confidential.  
 
6.5 Provisions to Moni tor the Study to Ensure the Safety of Subjects  
• The standard of care at Tufts Medical Center is to collect safety information on all patients 
undergoing surgery through an established computerized system called Anesthesia Touch. Safety 
information and adverse events that will be collected includes failure of spi[INVESTIGATOR_397369]. For the purpose s of this study, the principal investigator [INVESTIGATOR_212730] (every 6 
months) evaluate the safety data and assess the risks and benefits to assess subject safety.  The 
statistical tests that will be performed on the safety data to determine whether harm is occurring 
will include a chi -squared test, to compare proportions between groups.  
• Stoppi[INVESTIGATOR_1877]: should we observe [ADDRESS_500053] not experienced any problems .  
• No Data and Safety Monitoring Board will be used  in this study.  
 
6.6 Compensation for Research -Related Injury  
Does the research involve greater than minimal risk to subjects?  
  
6.7 Economic Burden to Subjects  
Does the research involve any costs to subjects?  
  
 
 
6.10 Vulnerable Populations  
Will pregnant women be enrolled?   
  
The study will be performed exclusively on pregnant women. Although the Food and Drug 
Administration has labeled one of the drugs in this study, chloroprocaine, as Category C risk in pregnancy , the 
risk to the fetus is likely very low. C hloroprocaine is metabolized very quickly  by [CONTACT_397395] , such 
that crossing the placenta and transmission to the fetus is exceedingly unlikely.  This was demonstrated by 
[CONTACT_397396]  [ADDRESS_500054] veins and neonatal plasma.  (7) Similarly, in a comparison of bupi[INVESTIGATOR_397370], Maes 
[ADDRESS_500055] gases, suggesting 
no harm to the fetus from chloroprocaine. (8) 
Given the amount of evidence suggesting no negative effects of chloroprocaine on the fetus, the local 
anesthetic is commonly used in pregnancy and is part of the standard of care for cervical cerclage  at Tufts 
Yes
No
Y es
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.[ADDRESS_500056] that another institution, Columbia University, is currently 
using chloroprocaine as part of a similar IRB -approved research study. Therefore, we believe t his study’s risk to 
the fetus is not greater tha n minimal risk. Given that the purpose of the research is the development of important 
biomedical knowledge  that cannot  be obtained by [CONTACT_86416], performance of this research is necessary.  
Furthermore, the benefits of chloroprocaine warrant the use o f this local anesthetic in pregnant women. 
The shorter the duration of motor block  with chloroprocaine decreases the duration of immobility, thereby 
[CONTACT_397397]  (DVT). Part icipa nts are at particularly high risk 
for developi[INVESTIGATOR_229434], and there is countless evidence that suggests pregnant women should ambulate as much as 
possible.  
 Regarding bupi[INVESTIGATOR_10319], preclinical studies, including studies on pregnant animals, and clinical studies, 
including studies on non -pregnant women, have been conducted and provide data for assessing potential risks to 
pregnant women and fetuses  (Maes 2006) . The benefit to the fetus is survival during the pregnancy; without the 
procedure, the mother will not be able to carry the fetus to  term and the fetus will deliver pre -term and die. T he 
risk to the fetus is NOT greater than Minimal Risk, and the purpose of the research is the development of 
important biomedical knowledge which cannot be obtained by [CONTACT_86416].  Any risk is the least possible for 
achieving the objectives of the research.  
Given that termination of pregnancy is irrelevant to this study, n o inducements, monetary or otherwise, 
will be offered to terminate a pregnancy . In the case of a fetus, the fetus is not the subj ect of a planned abortion.  
Furthermore, t he research team will have no part in any decisions as to the timing, method, or procedures used to 
terminate a pregnancy or in determining the viability of a neonate.  
 
Will the research involve neonates of uncertai n viability or non -viable neonates?  
  
     
Will subjects  who are not yet adults (neonates, children, teenagers) be enrolled?    
       
 
Will minors who are:  
i) married, widowed, divorced; or  
ii) the parent of a child; or  
iii) a member of any of the armed forces; or  
iv) pregnant or believes herself to be pregnant; or  
v) living separate and apa rt from his/her parent or legal guardian, and is managing his/her own 
financial affairs  
be approached for study participation for either themselves or their child?  
   
 
 
 
Will wards of the state and/or children at risk of becoming wards of the state be enro lled (this includes 
foster children or any child that is in state custody)?            
   
 
Will cognitively impaired adults (adults with impaired -decision making capacity) or adults who may lose 
the capacity to consent be enrolled?  
  
 
Will prisoners be enrolled?  
  
Will students and/or employees be enrolled in this research?  
 
 
 
7 Adverse Event Monitoring  
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 10 of 15  7.1 Definitions  
The study does not carry a higher risk of adverse events than typi[INVESTIGATOR_212732] . Adverse events may include 
side effects from spi[INVESTIGATOR_397371], vomiting , high spi[INVESTIGATOR_1304] , allergic reaction s, and systemic 
toxicity  in the event of unintended intravascular injection . Effects on the fetus are directly related to the 
effects on the mother.  
 
Adverse event: An adverse event is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal phys ical exam or laboratory finding, symptom, or disease, temporally associated with 
a subject’s participation in the research.  
 
Serious adverse reaction:  a serious medical occurrence associated with the use of a  bupi[INVESTIGATOR_397372], such as death.  
 
Unanticipated problems:  any incident, experience, or outcome that meets  all of the following criteria:  
unexpected ; related or possibly related to participation in the research ; and suggests that the research places 
subjects at a greater risk of harm than was previously known or recognized.   
 
7.2 Reporting Procedures  
Patients are routinely monitored for development of adverse events (such as asystole, severe hypotension 
(MAP<30), and apne a) as part of their anesthetic care.  This occurs on a continuous basis from the moment the 
anesthetic is administered until the moment the patient is discharged home. A computerized system exists 
which alerts clinicians to the development of some adverse effects, and is recorded in the medical record. The 
co-investigator, [CONTACT_397402], will be a lerted in these situations and all adverse events will be forwarded to the 
principal investigator. Clinicians are alerted to events immediately as they occur. Clinical staff are trained to 
deal with such events. The co-investigator, [CONTACT_397402],  will be responsible for contact[CONTACT_397398] [INVESTIGATOR_397373] s. The principal investigator [INVESTIGATOR_397374] , include the Anesthesia Department’s Quality Assurance form . The events will be 
reported within 24 hours to the QI director and the Chairman of the department , and to the IRB within 5 days .  
 
7.3 Reportable New Information  
Reportable new information will be reported to the IRB per the Tufts Health Sciences IRB’s “Reportable New 
Information policy ”. The PI [INVESTIGATOR_397375], rights, welfare o r willingness to take part in the research.  
 
 
8 Statistical Considerations  
8.1 Study Endpoints  
Primary endpoint: complete resolution of motor block  
Secondary endpoint : resolution of sensory block, ambulation , and micturation  
 
8.2 Statistical Analysis  
Given that our primary outcome is duration of motor block, we will compare the difference between two 
independent mean times using Student’s t-test. Given that our secondary outcomes are also duration, we will 
also use Student’s t-test to compare means bet ween the two independent variables. If any subjects withdraw 
from the trial prior to discharge, we will use the Kaplan -Meier method  as a secondary analysis. However, we 
will primarily use Student’s t-test in the analysis.  
 
8.3 Number of Subjects  
Yoos  2005 found that after the administration of 40mg chloroprocaine, the motor block resolves in 69 ± 16 
minutes.  (3)  Kiran  2002 found that after the administration of 7.5mg bupi[INVESTIGATOR_10319], the motor block resolves in 
100 ± 15 minutes. (9) We are designing this  study to observe a 30 minute time difference. Measuring in 10 
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 11 of 15  minute increments will be sufficient to find this difference.  To estimate the number of subjects needed for this 
study, the software G*Power 3.1 was used to perform  a power analysis with 80% po wer and alpha level of 
0.05 using the results from Yoos and Kiran . The power analysis revealed that a total of 8 study subjects will 
be needed. In order to account for 20% attrition rate, the total number of study subjects needed is 10.  
 
8.4 Data Management  
The d ata to be collected will be divided into  four general groups:  (1) demographi c data (e.g. age, height, etc.); 
(2) Time of local anesthetic injection; (3) time of resolution of motor block, sensory block, ambulation, and 
micturation. Data col lection forms and an excel spreadsheet with be used to organize the data and all of the 
analyzed data will be stored during the study period in the  principle investigator’s  locked office and hospi[INVESTIGATOR_397376], password protected,  Box account, where access is exclusive to the research team.  
 
8.5 Randomization  
Will subjects be randomized?  
  
In order to randomly allocate study subjects to one of two treatment arms entirely by [CONTACT_3364], we will use the 
on-line randomization tool “Research Randomizer Version 4.0, www.randomizer.org ,” which has been 
studied and validated as an adequate randomization tool, to generate a randomization list . (7) Allocation 
concealment will be maintained by [CONTACT_397399], seale d, opaque envelopes, which will 
contain the randomization assignment consistent with the generated randomization list.  
 
 The following strategies will be implemented in order to ensure blinding:  
(a) When a subject enrolls in the study, the anesthesia provider responsible for the clinical care of the patient 
will be given an envelope prepared during randomization. The anesthesia provider will be instructed to 
open the envelope and prepare the medicatio n in a separate room, such that the investigator and patient 
cannot see which vial is being used to prepare the medication. The anesthesia provider will also be 
instructed not to reveal the allocation group to the investigator or the patient.  
(b) Upon return to the operating room, the spi[INVESTIGATOR_397377]. Investigators will be unable to distinguish which medication is being 
administered just by [CONTACT_397400] b ecause both bupi[INVESTIGATOR_397378], 
and because the intended doses of both medications are the same volume.  
(c) The co-investigator  making clinical outcome assessments, [CONTACT_397402], has only research privileges but no 
clinical privileges. As a result, she  will be unable to administer any medication. This will be one more 
way to ensure blinding as she will not have any influence or knowledge of the spi[INVESTIGATOR_397379]  
(d) Study subjects will not be informed of which medication is administered.  
 
 
 
9 Drugs or Devices  
Will the research involve drugs ?   
  
Will the research involve devices?   
  
The anesthesia provider taking care of the patient  clinically  will prepare and administer the indicated medication, 
either chloroprocaine [ADDRESS_500057]’s expected clinical duties and are part of the standard of care. Although not every 
Yes
No
Yes
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 12 of 15  parturient is part of a research study, one could argue that receiving a “random” assignment is in fact part of the 
standard of care. It would not be unusual for our anesthesia residents to ask the attending  anesthesiologist to teach 
him or her how to use one or the other medication. If a resident often uses bupi[INVESTIGATOR_10319], he or she may want to 
learn and test out how to dose and use chloroprocaine. At that point, the attending would be having to use a 
medicatio n other than the one he or she may have originally intended. Both are acceptable choices for this 
procedure. Therefore, these providers should not be considered part of the research team. Both local anesthetics 
will be available to subjects after  complet ion of the study , although we do not anticipate that they would need any 
more local anesthetic  after the proce dure.    
 
According to the FDA, when the principal intent of the investigational use of an approved, marketed drug (such as 
chloroprocaine) is to de velop information about the product’s safety or efficacy, submission of an IND may be 
required. Please see the FDA website: https://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm   
However, according to 21 CFR 312.2(b)(1), the clinical investigation of a marketed drug or biologic does not 
require submission of an IND if all six of the following conditions are met:  
1) it is not intended to be reported to FDA in support of a new indication for use or to support any other 
significant change in the labeling for the drug;  
2) it is not intended to support a significant change in the advertising for the product;  
3) it does not involve a route of administration or dosage level, use in a subject population, or other factor 
that significantly increases the risks (or decreases the acceptability of the risks ) associated with the use of 
the drug product;  
4) it is conducted in compliance with the requirements for IRB review and informed consent [21 CFR parts 
56 and 50, respectively];  
5) it is conducted in compliance with the requirements concerning the promotion and sale of drugs [21 CFR 
312.7]; and  
6) it does not intend to invoke 21 CFR 50.24.  
In our study, all six conditions are met, therefore not requiring submission of an IND. The six conditions are met 
as follows: (1) we do not intend to report to the FDA in support  of a new indication for use or to support any other 
significant change in the labeling for chloroprocaine; (2) we do not intend to support a significant change in the 
advertising for the product; (3) we are not using this drug in a route of administration  or dosage level, use in a 
subject population, or other factor that significantly increases the risks (or decreases the acceptability of the risks) 
associated with the use of chloroprocaine*; (4) the study will be conducted in compliance with the requireme nts 
for IRB review and informed consent; (5) the study will be conducted in compliance with the requirements 
concerning the promotion and sale of drugs; and, (6) the study does not intend to invoke 21 CFR 50.24.  
 
*One concern that may arise when reading t he chloroprocaine label is that it states, “not to be used for 
subarachnoid administration.” However, chloroprocaine is very often used in the subarachnoid space “off -label,” 
and the restriction is a bit misleading. Below is an explanation of why the use o f chloroprocaine is safe, despi[INVESTIGATOR_397380].  
 
Regarding route of administration:  
 
Although the FDA writes that, “Nesacaine and Nesacaine -MPF Injections are not to be used for 
subarachnoid administration,” further reading of the labeling reveals the true intention of this statement. 
Throughout the package insert there are multiple references to signs and symptoms consistent with Total Spi[INVESTIGATOR_397381]. For example, “Unintentional subarachnoid 
injection of drug during the intended performance of caudal or lumbar epi[INVESTIGATOR_397382] (especially in the head and neck region) may result in underventilation or apnea (“Total 
Spi[INVESTIGATOR_1304]”).” The reason that the FDA writes that chl oroprocaine is not intended for subarachnoid injection is 
because large doses (300 -600mg) of chloroprocaine  can result in apnea and cardiovascular collapse. Small doses 
(30-60mg) are safe, do not result in total spi[INVESTIGATOR_1304], and are frequently the intended site  of injection for various 
surgical procedures.  
Multiple previous publications (Davis 2005, Gonter 2005, Warren 2004, Vath 2004, Yoos 2005, Lacasse 
2011, Smith 2004) have studied chloroprocaine as administered in the subarachnoid space. The authors did not 
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 13 of 15  observe any adverse effects with the use of subarachnoid chloroprocaine in the doses 10 -60mg. Furthermore, 
Hejtmanek 2011 reports that chloroprocaine, “ is widely used at Virginia Mason Medical Center, where we have 
performed over 4000 spi[INVESTIGATOR_397383].” These authors again observed no adverse events from the use of 
chloroprocaine in the subarachnoid space in over 4,000 patients. All of these different articles demonstrate that 
the subarachnoid route of administration does not significantly increase the ri sks (or decrease the acceptability of 
the risks) associated with the use of chloroprocaine.   
Given the safety profile of chloroprocaine in the subarachnoid space, clinicians throughout the United 
States use it on a regular basis for spi[INVESTIGATOR_18227]. Howe ver, some may still be concerned about the label. 
Therefore, in order to fully inform patients about the FDA warning, we will include in the informed consent that 
the chloroprocaine manufacturing label specifically states, “not for spi[INVESTIGATOR_18227].” We will further inform 
patients that the use is considered “off -label,” but has been used successfully in thousands of anesthetics.  
 
Regarding dosage level:  
 
Multiple previous publicat ions (Davis 2005, Gonter 2005, Warren 2004, Vath 2004, Yoos 2005, Lacasse 
2011, Smith 2004) have studied chloroprocaine in varying doses from 10 -60mg. All of them found no adverse 
events. These articles demonstrate that the use of 10 -60mg does not signific antly increase the risks (or decrease 
the acceptability of the risks) associated with the use of chloroprocaine.  
 
Regarding use in a pregnant population:  
 
Although chloroprocaine is considered pregnancy category C, chloroprocaine is used regularly in clin ical 
practice for cerclage as well as many other procedures in pregnancy. The risk of chloroprocaine crossing the 
placenta and reaching the fetus are exceedingly low. Chloroprocaine is metabolized rapi[INVESTIGATOR_397384], wh ich makes transmission to the fetus unlikely. This has been demonstrated 
in a study comparing varying doses of chloroprocaine, in which Philipson [ADDRESS_500058] anesth esia care in cerclage. Furthermore, the 
manufacturing label states that, despi[INVESTIGATOR_397385] C, “ this does not preclude the use of 
chloroprocaine at term for the production of obstetrical anesthesia.”  
Given all of the above mentioned evidence, the use of chloroprocaine in pregnancy does not significantly 
increase the risks (or decrease the acceptability of the risks) associated with the use of chloroprocaine.  
 
Given that all [ADDRESS_500059]. Basura,  will ensure the eligibility of subjects and  obtain their  informed consent  
before implementing  any study related interventions.   
 
PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 14 of 15  10.3 Resources Available  
 
The research team is composed of the following members:  
• Principle investigator : Dan Drzymalski, MD , Assistant  Professor of Anesthesiology  
o [CONTACT_154484] is responsible for the preparation, design, conduct, and administration of the 
study.   
• Co-investigator : Alaa Basura, MD , Postdoctoral research fellow   
o Responsible for writing the study’s protocol under the principle investigator’s  guidance, obtaining 
the informed consent , managing data collection and data analysis.  
• Co-investigator: Michael House, MD , Associate Professor of Obstetric and Gynecology  
o Dr. is  responsible for revising the study protocol, recruiting patients, and performing the study.  
 
Tufts Medical Center facilities provide medical resources that might be needed by [CONTACT_4866].  The average 
number of cervical cerclage procedures performed at Tufts Medical Center is [ADDRESS_500060] to subjects.  
    
10.5 Multi -Site Research  
Is this a mult i-site study where Tufts is the sponsor, primary grant recipi[INVESTIGATOR_841], or coordinating site?:  
  
 
10.6 Community -Based Participatory Research  
Will this study involve community -based participatory research?  
  
10.7 Sharing Results with Subjects  
Will results  (overall study results or individual subject results, such as results of investigational diagnostic 
tests, genetic tests, or incidental findings) be shared with subjects or others (e.g., the subject’s primary 
care physician or the subject’s treating physi cian)?   
  
 
Yes
No
Yes
No
Yes
No

PROTOCOL TITLE:  A Randomized Controlled Trial of Intrathecal Chloroprocaine vs. Bupi[INVESTIGATOR_397351]:  Drzymalski_Protocol_2017.0 9.18 
 
 Page 15 of 15  11 References  
 
1. Concepcion et al. Rational use of local anaesthetics.  Drugs 1984;27:256 –70. 
2. Lacasse  et al. Comparison of bupi[INVESTIGATOR_23183] 2 -chloroprocaine for spi[INVESTIGATOR_397386]: a double -blind randomized trial . Can J Anesth 2011; 58:384 –391. 
3. Yoos et al. S pi[INVESTIGATOR_1304] 2 -chloroprocaine: a comparison with small -dose bupi[INVESTIGATOR_397387]. Anesth 
Analg  2005 Feb;100(2):566 -572. 
4. Casati et al. Spi[INVESTIGATOR_397388] -Free 2 -Chlorprocaine for Outpatient Knee 
Arthroscopy: A Prospective, Randomized, Double -Blind Comparison. Anesth Analg : 2007 Apr. 
104(4):959 -964. 
5. Beilin  et al. Subarachnoid Small -Dose Bupi[INVESTIGATOR_397389] . Anesth 
Analg 2003;97:56 -61.  
6. Saghaei. A n Overview of Randomization and Minimization Programs for Randomized Clinical Trials. J 
Med Signals Sens . 2011 Jan -Apr; 1(1): 55–61 
7. Philipson et al. 2-Chloroprocaine for local perineal infiltration. Am J Obstet Gynecol. 1987 
Nov;157(5):1275 -8.  
8. Maes et al. Randomised controlled trial of spi[INVESTIGATOR_397390] 2 -chloroprocaine during 
caesarean section . Acta Anaesthes iologica Scandinavica  2016;60: 642–649.  
9. Kiran et al. A comparative study of three different doses of 0.5% hyperbaric bupi[INVESTIGATOR_397391] a in elective caesarean section. IJOA 2002; 11:185–189. 
10. FDA website regarding IND exemption. 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm  
11. Davis et al. Spi[INVESTIGATOR_1304] 2 -Chloroprocaine: The Effect of Added Clonidine Anesth Analg 2005;100:559 –65  
12. Gonter  et al. Spi[INVESTIGATOR_1304] 2 -Chloroprocaine: A Comparison with Procaine in Volunteers . Anesth Analg 
2005;100:573 –9  
13. Warren et al. Spi[INVESTIGATOR_1304] 2 -Chloroprocaine: The Effect of Added Dextrose Anesth Analg 2004;98:95 –101  
14. Vath et al. Spi[INVESTIGATOR_1304] 2 -Chloroprocaine: The Effect of Add ed Fentanyl . Anesth Analg 2004;98:89 –94  
15. Smith et al. Spi[INVESTIGATOR_1304] 2 -Chloroprocaine: A Dose -Ranging Study and the Effect of Added Epi[INVESTIGATOR_397392] 2004;98:81 –8  
16. Hejtmanek et al. Chloroprocaine for spi[INVESTIGATOR_18227]: a retrospective analysis Acta Anaest hesiol Scand 
2011; 55: 267 –272  
 
 
 